传奇生物CAR-T在美获批二线适应症今年销售额有望破10亿美元

经济观察网04-07

经济观察网记者瞿依贤经济观察网记者瞿依贤 4月6日，传奇生物（LEGN.US）宣布其CAR-T产品——西达基奥仑赛在美国获批用于复发或难治性多发性骨髓瘤患者的二线治疗。传奇生物合作伙伴强生预测，这款药今年的销售额会突破10亿美元。在所有CAR-T、双抗和抗体药物偶联物（ADC）药物中，西达基奥仑赛是全球首个且唯一获批用于多发性骨髓瘤患者二线治疗的B细胞成熟抗原（BCMA）靶向疗法。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2425610426?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-07 21:18","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2425610426","market":"us","top_or_hot":-1,"title":"传奇生物CAR-T在美获批二线适应症 今年销售额有望破10亿美元","media":"经济观察网","content":"<div>\n<p>经济观察网 记者 瞿依贤 经济观察网 记者 瞿依贤 4月6日，传奇生物（LEGN.US）宣布其CAR-T产品——西达基奥仑赛在美国获批用于复发或难治性多发性骨髓瘤患者的二线治疗。传奇生物合作伙伴强生预测，这款药今年的销售额会突破10亿美元。在所有CAR-T、双抗和抗体药物偶联物（ADC）药物中，西达基奥仑赛是全球首个且唯一获批用于多发性骨髓瘤患者二线治疗的B细胞成熟抗原（BCMA）靶向疗法。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404072125318afab5e7&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>传奇生物CAR-T在美获批二线适应症 今年销售额有望破10亿美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n传奇生物CAR-T在美获批二线适应症 今年销售额有望破10亿美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-07 21:18 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404072125318afab5e7&s=b><strong>经济观察网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>经济观察网 记者 瞿依贤 经济观察网 记者 瞿依贤 4月6日，传奇生物（LEGN.US）宣布其CAR-T产品——西达基奥仑赛在美国获批用于复发或难治性多发性骨髓瘤患者的二线治疗。传奇生物合作伙伴强生预测，这款药今年的销售额会突破10亿美元。在所有CAR-T、双抗和抗体药物偶联物（ADC）药物中，西达基奥仑赛是全球首个且唯一获批用于多发性骨髓瘤患者二线治疗的B细胞成熟抗原（BCMA）靶向疗法。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404072125318afab5e7&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1280957306.USD","symbol_name":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404072125318afab5e7&s=b","article_id":"2425610426","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404072125318afab5e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2425610426","pubTimestamp":1712495919,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"经济观察网 记者 瞿依贤 经济观察网 记者 瞿依贤 4月6日，传奇生物宣布其CAR-T产品——西达基奥仑赛在美国获批用于复发或难治性多发性骨髓瘤患者的二线治疗。传奇生物合作伙伴强生预测，这款药今年的销售额会突破10亿美元。西达基奥仑赛自美国上市以后的累计销售额为6.3亿美元，其中2023年的销售额超过5亿美元。强生则预计，二线适应症在美国获批后，西达基奥仑赛今年的销售收入将突破10亿美元，未来的销售峰值会超过50亿美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","BK4007":"制药","SG9999002232.USD":"Allianz Global High Payout USD","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (SGDHDG) INC","BK4559":"巴菲特持仓","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","JNJ":"强生","LEGN":"传奇生物","BK4588":"碎股","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4022":"陆运","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","CAR":"安飞士","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","BK4230":"旅客陆运","BK4505":"高瓴资本持仓","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BK4581":"高盛持仓","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","BK4504":"桥水持仓","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","BK4532":"文艺复兴科技持仓","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","BK4592":"伊斯兰概念","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU1732800096.USD":"摩根大通环球收益基金A (irc)","BK4585":"ETF&股票定投概念","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4139":"生物科技"},"translate_title":"Legendary bio-CAR-T has been approved for second-line indications in the United States. Sales this year are expected to exceed 1 billion US dollars","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LEGN":1,"CAR":1,"JNJ":0.9},"content_text":"经济观察网 记者 瞿依贤 经济观察网 记者 瞿依贤 4月6日，传奇生物（LEGN.US）宣布其CAR-T产品——西达基奥仑赛在美国获批用于复发或难治性多发性骨髓瘤患者的二线治疗。传奇生物合作伙伴强生预测，这款药今年的销售额会突破10亿美元。在所有CAR-T、双抗和抗体药物偶联物（ADC）药物中，西达基奥仑赛是全球首个且唯一获批用于多发性骨髓瘤患者二线治疗的B细胞成熟抗原（BCMA）靶向疗法。2022年3月，西达基奥仑赛正式在美国获批，用于治疗复发或难治性多发性骨髓瘤患者的末线治疗。这是美国食品药品监督管理局（FDA）批准的首款中国产CAR-T细胞疗法，也是美国市场第二款以BCMA为靶点的CAR-T疗法。从国内进度来看，2022年12月，传奇生物向国家药监局递交了西达基奥仑赛的上市申请，但未在国内“拔得头筹”。2023年6月，驯鹿生物和信达生物（01801.HK）合作开发的靶向BCMA的CAR-T疗法伊基奥仑赛获批上市。2024年3月，科济生物靶向BCMA的泽沃基奥仑赛也获批。传奇生物对经济观察网表示，西达基奥仑赛有望今年年中在国内上市。如果在国内上市，西达基奥仑赛将成为国内第六款CAR-T、第三款靶向BCMA的CAR-T。西达基奥仑赛在美国的定价是46.5万美元，但国内目前已有的5款CAR-T定价在99.9万元—129万元。这款药在国内的定价也备受关注。在国产创新药“出海”的话题上，西达基奥仑赛是一个样本——早在2017年就跟强生签订了全球独家许可和合作协议，共同开发和商业化这款产品。强生方面向传奇生物支付3.5亿美元首付款及后续里程碑付款，这在当时是中国药企对外专利授权首付款最大金额纪录及合作最优条件。西达基奥仑赛自美国上市以后的累计销售额为6.3亿美元，其中2023年的销售额超过5亿美元。根据当时签署的协议，在大中华地区，强生与传奇生物将以3：7的比例共同承担成本和分享收益；除此之外的全球其他地区，约定比例则为5：5。《Nature》杂志曾发文预测，西达基奥仑赛在2027年将成为全球最畅销的细胞疗法。强生则预计，二线适应症在美国获批后，西达基奥仑赛今年的销售收入将突破10亿美元，未来的销售峰值会超过50亿美元。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2425610426"}

传奇生物CAR-T在美获批二线适应症 今年销售额有望破10亿美元

精彩评论

传奇生物CAR-T在美获批二线适应症今年销售额有望破10亿美元